AIP
CLDX icon

Ameritas Investment Partners’s Celldex Therapeutics CLDX Stock Holding History

Ameritas Investment Partners’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$264K Buy
7,094
+1,622
+30% +$52.4K 0.01% 1227
2026
Q1 		$174K Hold
5,472
– – 0.01% 1348
2025
Q4 		$149K Hold
5,472
– – ﹤0.01% 1447
2025
Q3 		$142K Sell
5,472
-1,072
-16% -$24.8K ﹤0.01% 1462
2025
Q2 		$133K Hold
6,544
– – ﹤0.01% 1561
2025
Q1 		$119K Hold
6,544
– – ﹤0.01% 1584
2024
Q4 		$165K Hold
6,544
– – 0.01% 1434
2024
Q3 		$222K Buy
6,544
+346
+6% +$13.2K 0.01% 1249
2024
Q2 		$229K Hold
6,198
– – 0.01% 1174
2024
Q1 		$260K Buy
6,198
+1,582
+34% +$65K 0.01% 1122
2023
Q4 		$183K Hold
4,616
– – 0.01% 1320
2023
Q3 		$127K Buy
4,616
+779
+20% +$24.4K 0.01% 1488
2023
Q2 		$130K Buy
3,837
+312
+9% +$10.5K ﹤0.01% 1408
2023
Q1 		$127K Hold
3,525
– – 0.01% 1373
2022
Q4 		$164K Hold
3,525
– – 0.01% 1267
2022
Q3 		$99K Hold
3,525
– – ﹤0.01% 1493
2022
Q2 		$95K Hold
3,525
– – ﹤0.01% 1544
2022
Q1 		$120K Hold
3,525
– – ﹤0.01% 1511
2021
Q4 		$136K Hold
3,525
– – ﹤0.01% 1498
2021
Q3 		$190K Buy
3,525
+451
+15% +$21.2K 0.01% 1237
2021
Q2 		$103K Buy
+3,074
New +$84.4K ﹤0.01% 1705
2018
Q2 		– Sell
-690
Closed -$24K – 3008
2018
Q1 		$24K Hold
690
– – ﹤0.01% 2319
2017
Q4 		$29K Buy
690
+183
+36% +$7.84K ﹤0.01% 2237
2017
Q3 		$18K Hold
507
– – ﹤0.01% 2474
2017
Q2 		$19K Hold
507
– – ﹤0.01% 2478
2017
Q1 		$27K Buy
+507
New +$26.4K ﹤0.01% 2225
2015
Q2 		– Sell
-524
Closed -$219K – 1173
2015
Q1 		$219K Buy
+524
New +$187K 0.01% 972
2013
Q4 		– Sell
-477
Closed -$253K – 1065
2013
Q3 		$253K Buy
+477
New +$164K 0.02% 826

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ameritas Investment Partners's CLDX Position: Q2 2026 in Review

Ameritas Investment Partners increased its Celldex Therapeutics (CLDX) stake by 30% in Q2 2026, buying an estimated $52.4K and bringing the position to 7,094 shares worth $264K. The position accounts for 0.01% of the portfolio, ranked #1227.

Ameritas Investment Partners first reported a position in CLDX in Q3 2013 and has held it in 28 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Ameritas Investment Partners held 7,094 shares of Celldex Therapeutics worth $264K as of Q2 2026.
  • Ameritas Investment Partners bought 1,622 Celldex Therapeutics shares in Q2 2026, an estimated $52.4K.
  • Celldex Therapeutics made up 0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #1227 holding.
  • Ameritas Investment Partners first reported a position in Celldex Therapeutics in Q3 2013 and has held it in 28 quarters since.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.